Synthesis, molecular modeling, and biological evaluation of cinnamic acid metronidazole ester derivatives as novel anticancer agents

Bioorg Med Chem. 2010 Jul 15;18(14):4991-6. doi: 10.1016/j.bmc.2010.06.003. Epub 2010 Jun 8.

Abstract

A series of novel cinnamic acid metronidazole ester derivatives have been designed and synthesized, and their biological activities were also evaluated as potential EGFR and HER-2 kinase inhibitors. Compound 3h showed the most potent biological activity (IC50=0.62 microM for EGFR and IC50=2.15 microM for HER-2). Docking simulation was performed to position compound 3h into the EGFR active site to determine the probable binding model. Antiproliferative assay results demonstrated that some of these compounds possessed good antiproliferative activity against MCF-7. Compound 3h with potent inhibitory activity in tumor growth inhibition may be a potential anticancer agent.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology*
  • Breast Neoplasms / drug therapy*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cinnamates / chemical synthesis
  • Cinnamates / chemistry*
  • Cinnamates / pharmacology*
  • Crystallography, X-Ray
  • Drug Screening Assays, Antitumor
  • ErbB Receptors / chemistry
  • ErbB Receptors / metabolism*
  • Female
  • Humans
  • Metronidazole / chemical synthesis
  • Metronidazole / chemistry*
  • Metronidazole / pharmacology*
  • Models, Molecular
  • Receptor, ErbB-2 / metabolism

Substances

  • Antineoplastic Agents
  • Cinnamates
  • cinnamic acid
  • Metronidazole
  • ERBB2 protein, human
  • ErbB Receptors
  • Receptor, ErbB-2